Loading cancer entity…
Subtype
CI-CAN-00002836HNSCC · SCCHNExplore in graph →
Clinical trials
1,589 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (247)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05008796 | PD-L1 Expression on CTCs in HNSCC Patients Underwent Curative CCRT | unknown | — | 50 | Chang Gung Memorial HospitalOTHER | 1 | Aug 18, 2021 | clinicaltrials |
| NCT04999800 | Study of Pembrolizumab Combined With Anlotinib in the First Line Therapy for R/M HNSCC With CPS≥1 | unknown | Phase 2 | 20 | Shi YuankaiUNKNOWN | 1 | Aug 11, 2021 | clinicaltrials |
| NCT03450967 |
| Durvalumab Plus Tremelimumab Combined With Proton Therapy for HNSCC |
| unknown |
| Phase 2 |
| 31 |
| Samsung Medical CenterOTHER |
| 1 |
| Aug 10, 2021 |
| clinicaltrials |
| NCT04270201 | Determination of ALDH1b1 and ALDH2 Polymorphisms Frequency in the Brazilian Population(ALDH2020) | unknown | — | 300 | Instituto do Cancer do Estado de São PauloOTHER | 1 | May 19, 2021 | clinicaltrials |
| NCT04882462 | Sintilimab and Nimotuzumab Combined With Chemotherapy for the Treatment of R/M HNSCC.(Carpp-1) | unknown | Phase 2 | 100 | The First Affiliated Hospital of Soochow UniversityOTHER | 0 | May 12, 2021 | clinicaltrials |
| NCT03134846 | Image Guided Surgery for Margin Assessment of Head and Neck Cancer Using Cetuximab-IRDye800CW cONjugate(ICON) | unknown | Phase 1 / Phase 2 | 79 | University Medical Center GroningenOTHER | 1 | May 3, 2021 | clinicaltrials |
| NCT04861467 | Camrelizumab as a Maintenance Therapy After Chemoradiation in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma | unknown | Phase 2 | 155 | Chinese Academy of Medical SciencesOTHER | 1 | Apr 27, 2021 | clinicaltrials |
| NCT04523883 | Concurrent Immunotherapy With Postoperative Radiotherapy in Intermediate/High Risk HNSCC Patients Unfit for Cisplatin: The IMPORT Study (IMPORT)(IMPORT) | unknown | Phase 2 | 316 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityOTHER | 1 | Apr 15, 2021 | clinicaltrials |
| NCT02661152 | DAHANCA 30: A Randomized Non-inferiority Trial of Hypoxia-profile Guided Hypoxic Modification of Radiotherapy of HNSCC.(DAHANCA30) | unknown | Phase 3 | 1,252 | Danish Head and Neck Cancer GroupNETWORK | 1 | Apr 13, 2021 | clinicaltrials |
| NCT04196985 | 18F-FDG PET/CT Versus 18F-FDG PET/MRI in Detecting Locoregional Recurrence 3 Months After CRT in Head and Neck SCC(HENEPET) | unknown | N/A | 40 | Turku University HospitalOTHER_GOV | 1 | Apr 13, 2021 | clinicaltrials |
| NCT04832555 | Non Elective Vulnerable Elderly Radiotherapy(NEVER) | unknown | N/A | 100 | Azienda Ospedaliero Universitaria Policlinico ModenaOTHER | 1 | Apr 6, 2021 | clinicaltrials |
| NCT04826679 | Neoadjuvant Camrelizumab in Combination With Cisplatin and Nab-paclitaxel in Resectable HNSCC | unknown | Phase 2 | 53 | Sun Yat-sen UniversityOTHER | 1 | Apr 1, 2021 | clinicaltrials |
| NCT03771820 | Combination Therapy With NC-6004 and Pembrolizumab in Head and Neck Cancer Subjects Who Have Failed Platinum Regimen | unknown | Phase 2 | 136 | NanoCarrier Co., Ltd.INDUSTRY | 8 | Mar 17, 2021 | clinicaltrials |
| NCT02054442 | A Study of the Combination of Cetuximab and Methotrexate in Recurrent or Metastatic Cancer of the Head and Neck(COMMENCE) | unknown | Phase 1 / Phase 2 | 52 | Radboud University Medical CenterOTHER | 1 | Mar 12, 2021 | clinicaltrials |
| NCT04780750 | Concurent Chemoradiotherapy in Head and Neck Cancers | unknown | Phase 3 | 60 | Assiut UniversityOTHER | 0 | Mar 3, 2021 | clinicaltrials |
| NCT04766827 | Albumin-bound Paclitaxel Combined With Cisplatin Versus Docetaxel Combined With Cisplatin Induced Chemotherapy in Advanced Head and Neck Squamous Tummor | unknown | Phase 4 | 116 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Feb 23, 2021 | clinicaltrials |
| NCT04440917 | Camrelizumab Combined With Apatinib Mesylate for Head and Neck Squamous Cell Carcinoma(IMplus) | unknown | Phase 2 | 32 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityOTHER | 1 | Feb 2, 2021 | clinicaltrials |
| NCT03908372 | Optimized Treatment Strategies for Early and Medium Stage Nasopharyngeal Carcinoma | unknown | Phase 2 / Phase 3 | 120 | Chinese Academy of Medical SciencesOTHER | 1 | Jan 29, 2021 | clinicaltrials |
| NCT04543266 | Predicting Metastatic Oral Squamous Cell Carcinomas With Molecular Biomarkers Using Machine Learning | unknown | — | 500 | The University of Hong KongOTHER | 1 | Sep 11, 2020 | clinicaltrials |
| NCT04279509 | Selecting Chemotherapy With High-throughput Drug Screen Assay Using Patient Derived Organoids in Patients With Refractory Solid Tumours (SCORE) | unknown | N/A | 35 | National University Hospital, SingaporeOTHER | 1 | Sep 9, 2020 | clinicaltrials |
| NCT03196843 | Radiotherapy Combine With Raltitrexed Versus Radiotherapy Alone in Older Patients With HNSCC. | unknown | Phase 4 | 202 | The First Affiliated Hospital of Dalian Medical UniversityOTHER | 1 | Aug 7, 2020 | clinicaltrials |
| NCT03874741 | SCT200 Plus Platinum-based Chemotherapy in Head and Neck Squamous Cell Carcinoma | unknown | Phase 2 | 25 | Sinocelltech Ltd.INDUSTRY | 1 | May 27, 2020 | clinicaltrials |
| NCT04399785 | Phase II Study for Combination of Camrelizumab and SBRT in the First-line Treatment for R/M HNSCC | unknown | Phase 2 | 34 | Xingchen PengOTHER | 1 | May 22, 2020 | clinicaltrials |
| NCT04387682 | Myeloid-derived Suppressor Cells (MDSCs) in OSCC Patients | unknown | N/A | 130 | National Taiwan University HospitalOTHER | 1 | May 14, 2020 | clinicaltrials |
| NCT03440151 | Oncological Outcome of Contralateral Submental Artery Island Flap Versus Primary Closure in Tongue Squamous Cell Carcinoma | unknown | N/A | 64 | Cairo UniversityOTHER | 1 | Apr 14, 2020 | clinicaltrials |
| NCT04296747 | Toripalimab in Combination With Chemotherapy as Induced Chemotherapy for Localized Hypopharyngeal Cancer | unknown | Phase 2 | 100 | Peking Union Medical College HospitalOTHER | 0 | Mar 5, 2020 | clinicaltrials |
| NCT04146402 | SCT-I10A Plus Standard Chemotherapy in First-line Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma | unknown | Phase 3 | 330 | Sinocelltech Ltd.INDUSTRY | 1 | Feb 5, 2020 | clinicaltrials |
| NCT03418454 | The Oral Microbiome as a Prognostic Tool in Oral Malignant and Premalignant Lesions and in Medication Related Osteonecrosis of the Jaw | unknown | — | 150 | Barzilai Medical CenterOTHER | 1 | Jan 18, 2020 | clinicaltrials |
| NCT04222543 | Imaging of Tumour Microenvironment in Patients With Oropharyngeal Head and Neck Squamous Cell Carcinoma Using RGD PET/CT Imaging(PIVOT) | unknown | Phase 2 | 20 | Radboud University Medical CenterOTHER | 1 | Jan 10, 2020 | clinicaltrials |
| NCT04146181 | Safety and Efficacy of SCT-I10A in Head and Neck Squamous Cell Carcinoma | unknown | Phase 2 | 103 | Sinocelltech Ltd.INDUSTRY | 1 | Dec 12, 2019 | clinicaltrials |
| NCT04164238 | Neoadjuvant Anti-PD-1 Antibody (Toripalimab) or Combined With Chemotherapy in HNSCC Patients | unknown | Phase 2 | 90 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Nov 15, 2019 | clinicaltrials |
| NCT03855384 | Study of TQB2450 in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck（R/M SCCHN） | unknown | Phase 3 | 334 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Oct 30, 2019 | clinicaltrials |
| NCT04117139 | The Diagnostic Value of PET/MRI in Head and Neck Cancer | unknown | N/A | 142 | Odense University HospitalOTHER | 1 | Oct 8, 2019 | clinicaltrials |
| NCT02765503 | Resource Sparing Curative Radiotherapy for Locally Advanced Squamous Cell Cancer of the Head and Neck: The HYPNO Trial(HYPNO) | unknown | N/A | 836 | International Atomic Energy AgencyOTHER_GOV | 9 | Aug 8, 2019 | clinicaltrials |
| NCT03830385 | Paclitaxel (Albumin Bound),Bleomycin And Cisplatin Or Carboplatin for Recurrent Or Metastatic Squamous Cell Carcinoma Of The Head And Neck | unknown | Phase 2 | 51 | Sun Yat-sen UniversityOTHER | 1 | Jul 16, 2019 | clinicaltrials |
| NCT03926468 | Liquid Biopsy in Head and Neck Cancer | unknown | — | 30 | Turku University HospitalOTHER_GOV | 1 | Jun 4, 2019 | clinicaltrials |
| NCT02663583 | Intensity-Modulated Proton Therapy (IMPT) or TransOral Robotic Surgery (TORS) for the Treatment of Low-Risk Oropharynx Squamous Cell | unknown | — | 44 | M.D. Anderson Cancer CenterOTHER | 1 | May 23, 2019 | clinicaltrials |
| NCT03938012 | Evaluating Mutations in MET and TP53 Among Patients Diagnosed With Squamous Cell Carcinoma | unknown | — | 80 | National University Hospital, SingaporeOTHER | 1 | May 6, 2019 | clinicaltrials |
| NCT03917537 | WGA in Platinum-refractory HNSCC Underwent Nivolumab | unknown | — | 80 | Chang Gung Memorial HospitalOTHER | 1 | Apr 25, 2019 | clinicaltrials |
| NCT03917524 | Feasibility of CTCs Isolation for Transcriptomes and Genome Wide Associated Analysis in Post-OP High Risk OSCC Patients.(CTC) | unknown | — | 180 | Chang Gung Memorial HospitalOTHER | 1 | Apr 17, 2019 | clinicaltrials |
| NCT02216916 | Phase II Trial of HM781-36B in Patients With Metastatic/Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) After Failure of or Unfit for Platinum-containing Therapy | unknown | Phase 2 | 49 | Yonsei UniversityOTHER | 1 | Mar 18, 2019 | clinicaltrials |
| NCT03843671 | Hyperbaric Radiation Sensitization of Head and Neck Cancers | unknown | Phase 2 | 400 | National Baromedical ServicesOTHER | 2 | Feb 18, 2019 | clinicaltrials |
| NCT03121313 | Maintenance Tegafur-uracil in Resected Oral Cavity Cancer With ECS+ | unknown | Phase 2 | 68 | Chang Gung Memorial HospitalOTHER | 1 | Feb 12, 2019 | clinicaltrials |
| NCT02433626 | Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Malignancies(COTI2-101) | unknown | Phase 1 | 51 | Critical Outcome Technologies Inc.INDUSTRY | 1 | Feb 1, 2019 | clinicaltrials |
| NCT03619304 | Assessment of Anti-cancerous Effect of Green, Roasted and Decaffeinated Coffee on Oral Squamous Cell Carcinoma Cell Line | unknown | N/A | 20 | Cairo UniversityOTHER | 0 | Jan 30, 2019 | clinicaltrials |
| NCT03744208 | SCT200 Injection in Patients With Head and Neck Squamous Cell Carcinoma | unknown | Phase 2 | 30 | Shi YuankaiUNKNOWN | 0 | Nov 16, 2018 | clinicaltrials |
| NCT03727594 | Radioguided Selective Neck Dissection for Staging and Treatment of Oral Cavity and Oropharyngeal Squamous Cell Carcinoma | unknown | — | 50 | University Hospital of FerraraOTHER | 1 | Nov 1, 2018 | clinicaltrials |
| NCT03529604 | Salivary Ap4A, SCCA, TROP2 in Oral Cancer Patients(OCSALTM) | unknown | — | 100 | University of ZagrebOTHER | 0 | Oct 16, 2018 | clinicaltrials |
| NCT03053661 | Immune Response Evaluation to Curative Conventional Therapy(IRECT-01) | unknown | — | 22 | University of UlmOTHER | 0 | Oct 11, 2018 | clinicaltrials |
| NCT03096184 | A Study of Apatinib Plus Tegafur Gimeracil Oteracil in Recurrent/Metastatic Head and Neck Cancers | unknown | Phase 2 | 38 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityOTHER | 1 | Oct 9, 2018 | clinicaltrials |
Data updated 22 days agoSource updated Aug 18, 2021source: clinicaltrials